Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

“The impact of Wegovy on the obesity market has been huge. key opinion leaders (KOLs) interviewed by GlobalData defined it as ‘revolutionary’. Now with Zepbound, the revolution continues ...

Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market ... trial that examined the impact of both drugs on patients ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound ... the market, it could significantly impact ...

Notably, both Zepbound ... treatment market, and these dips should be viewed as opportunities to enter the stock. Concerns about CVS dropping Zepbound seem overblown, with the impact expected ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...